Company Overview and News
In a bid to simplify its corporate structure, Enbridge Inc. (ENB - Free Report) has agreed to purchase all of the outstanding stocks of three North American units — Enbridge Energy Partners, L.P. (EEP - Free Report) , Enbridge Energy Management, L.L.C. (EEQ - Free Report) and Enbridge Income Fund Holdings Inc — for about $7.1 billion. The consolidation is related to the Federal Energy Regulatory Commission (FERC) tax overhaul, announced in March to reduce certain benefits for the master limited partnerships (MLPs).
ENB ENBBF EBGUF UNP EBBNF ENB EEP SEP
As per North Dakota’s oil regulator, the state’s daily crude output rose 3.4% in July after edging down 1.6% in the previous month. The North Dakota Department of Mineral Resources’ (‘DMR’) latest data said that oil production in July averaged a record 1,269,366 barrels a day, up 42,046 barrels a day from June. To put this in perspective, oil supplies from the state of North Dakota is now at par with the struggling OPEC producer Venezuela.
ENBBF WLL PSX CTLR MALRY ENB MPC MIN ENB ETP OAS EBBNF CLR MALRF
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
ENBBF ENB EBGUF EBBNF ENB L
(Bloomberg) -- Enbridge Inc. agreed to acquire the shares it doesn’t already own in three North American units for about $7.1 billion as the Canadian pipeline giant moves to simplify its corporate structure.
ENBBF ENB EBGUF EBBNF ENB EEP L SEP
Kinder Morgan Inc (KMI - Free Report) has reportedly hired investment bank, TD Securities, for the scheduled sale of its Canadian business. The sale, which will indicate the U.S. pipeline giant’s exit from Canada, is expected to raise about C$2.4 billion ($1.8 billion). At a conference in September, Kinder Morgan’s chief executive expressed intent in divesting the remaining Canadian business, which was initially purchased to support the Trans Mountain project.
ENBBF MEG ENB ENB KMI MEGEF EBBNF BIP KMR CVB KMRFZ
TORONTO/NEW YORK (Reuters) - Kinder Morgan Inc (KMI.N) has hired investment bank TD Securities (TD.TO) to facilitate a potential sale of its Canadian business, which could fetch as much as C$2.4 billion ($1.8 billion), people familiar with the situation told Reuters this week.
ENBBF KML MEG ENB ENB KMI MEGEF EBBNF BIP KMR CVB KMRFZ
Oil production is surging in North America but producers are far from happy as their profit margin is sinking. They are struggling to stay competitive owing to the infrastructural bottlenecks. As if the pipeline pinch problem was not enough for the United States and Canada, raging protests against the already approved and existing pipeline projects have made things worse.
DCUB SOJA DCUA DCUD DCUC CY UGI WGL ENB SJIU EQM KMI DRUA TRP EBBNF PAA ED KMR CVB NEE SO ENBBF DUKH TRP SJI D NJR DUK RGCO ENB ETP KMRFZ GJP
Chicago, IL –August 29, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Eclipse Resources Corporation (ECR - Free Report) , Schlumberger Limited (SLB - Free Report) , Enbridge Inc. (ENB - Free Report) , Plains All American Pipeline, L.
ECR ENBBF SLB BRMR DTK ENB SEP ENB EBBNF SCL SLB URBN PAA MMP
A court decision expected Thursday could determine the fate of the contentious Trans Mountain pipeline expansion and further define Canada's duty to consult with First Nations, experts say.
ENBBF ENB KML KMI EBBNF ENB KMR KMRFZ CVB
2018-08-28 zacks - 1
On the news front, Eclipse Resources Corp. (ECR - Free Report) agreed to combine with peer Blue Ridge Mountain Resources to form a $1.4 billion natural gas biggie, while oilfield services behemoth Schlumberger Ltd. (SLB - Free Report) agreed to offload its marine seismic acquisition business for $600 million.
ECR ENBBF SLB BRMR DTK ENB MGY SEP ENB BHI EBBNF SCL SLB PAA MMP RIG SGAZF
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET